This might be the fastest turn around we have done. Thanks to Vlado Perkovic and Brendon Neuen for joining us from Stockholm

#Prediabetes : Need to broaden focus from slowing progression to #T2D to ↓ cardio-kidney risk at earlier stage

✅ Risk appreciable at glycemic thresholds <6.5%

✅ Greater population attributable risk than T2D

✅ Risk modifiable?
#SELECT largely a CVOT of #GLP1RA in prediabetes

AJKD Matthew Sparks, MD Anna Burgner MD MEHP NoWars Elena Cervantes Jeff Kott Mineralocorticoid receptor antagonists vs Aldosterone synthase inhibitors 𝙼𝚊𝚝𝚝 𝙻𝚞𝚝𝚑𝚎𝚛 Anand Vaidya

New Drugs vs device therapy in hypertension aka ERAs, ASIs, Zilbesiran & denervation

All at once versus sequential therapy in DKD
#TheTimeIsNow Brendon Neuen

#NephMadness

Last week I learned that Matthias Diebold and team used the Git repository I created for eGFR slope to check & validate the results of their trial of felzartamab for antibody-mediated rejection in NEJM

🔗 Github github.com/SGLT2-Trialist…

🔗 NEJM nejm.org/doi/full/10.10…

🧵 1/4

📢 Time to Prioritize Kidney Health in Heart Failure

New #TRANSLATEHF data now out in JAMA Cardiology

In >80K Medicare beneficiaries in #GWTGHF registry, almost 2 in 3 have eGFR<60 at 🏥 discharge & over 1 in 20 progress to requiring dialysis within just 1y

jamanetwork.com/journals/jamac…

In the company of absolute greatness ☺️ Beyond inspired by these two incredible women and what they have done for Nephrology Katherine Tuttle Julie R Ingelfinger #ERA2024 Women In Nephrology

New #DontMissABeat

Fresh off #ERA24 , @BrendonNeuen joins @MVaduganathan & @SJGreene_MD to discuss semaglutide, FLOW, and the future of cardiorenal protection.
hcplive.com/view/dont-miss…

#Nephrology #Cardiology

I am getting this question a lot, so I'll try to rephrase! Another way to think of it:

Comparison in the top panel is SGLT2i + GLP-1RA vs GLP-1RA alone (everyone on GLP-1RA)

Bottom is SGLT2i vs placebo (no-one on GLP-1RA)

Clear benefit of SGLT2i on top of GLP-1RA #ERA24

Great to see the George-led SMART-C study sparking discussions with the latest results presented at #ERA24 this week.

The trial provides important efficacy & safety evidence to inform the clinical use of SGLT2 inhibitors and GLP-1 receptor agonists in combination.

ERA - European Renal Association

I am getting this question a lot, so I'll try to rephrase! Another way to think of it:

Comparison in the top panel is SGLT2i + GLP-1RA vs GLP-1RA alone (everyone on GLP-1RA)

Bottom is SGLT2i vs placebo (no-one on GLP-1RA)

Clear benefit of SGLT2i on top of GLP-1RA #ERA24

🔴🔴Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With #HF
#PARADIGM -HF

👥 1,910 (23% of total) with available data, 42%, 32%, and 26% were classi fied as low,
moderate, and high/very high KDIGO risk, respectively

👉 👥 with HFrEF,

Finally released: Felzartamab in late AMR! @MayerKatharinaa sharing the results at #ERA2024 !

nejm.org/doi/full/10.10…

Icing on the cake for me after a fantastic #ERA24 :

Matthias Diebold let me know the SMART-C GitHub (CREDENCE GFR slope code) was used to check & validate results for their trial in NEJM! nejm.org/doi/full/10.10…

Publications, slides & SMART-C GitHub at SMART-C.net

Details of the SMART-C analysis of the effects of SGLT2i by baseline GLP-1RA are in press in The Lancet Diabetes & Endocrinology

Full slide deck now available for download at SMART-C.net/resources

#ERA24 ERA - European Renal Association

Swapnil Hiremath @[email protected] ERA - European Renal Association The New York Times CNN Reuters Bloomberg The Telegraph 4/ Here are all #ERA24 LBCT

(So, we had 4 sessions after all Swapnil Hiremath @[email protected])

Effect of Avenciguat on Albuminuria in Patients with CKD: Two Randomized Placebo-Controlled Trials from JASN_News Hiddo Heerspink Sydney Tang Masaomi Nangaku
#ERA24 🇸🇪 #Nephpearls

👉🏼 journals.lww.com/jasn/abstract/…

And she is in! Congratulazioni 🇮🇹 and to all the new council members! All women 🥳 Kitty Jagar 🇳🇱 and Siren Sezar 🇹🇷 Fabulous news for inclusivity 😍

Swapnil Hiremath @[email protected] Cristina Popa ERA - European Renal Association American Society of Nephrology Agreed. An absolute blowout of a meeting.

These P2b data set the scene for the POSIBIL6 P3 trial - testing inflammation/CV hypothesis in dialysis

- 2000+ patients on dialysis (HD & PD)
- Clazakimab vs placebo
- Primary outcome: CV death or nonfatal MI

More data from P2b being shared later this year

#ERA24 ERA - European Renal Association